The Patent Finder

Oryzon Genomics, S.A.

24 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

2
Ending by 2030
Oct 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (US 10,329,256) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 1 fee due Apr 6, 2027
    The maintenance fee for Lysine specific demethylase-1 inhibitors and their use (US 9,149,447) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
  • 1 fee due May 10, 2027
    The maintenance fee for Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (US 9,181,198) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,524,717Oxidase inhibitors and their use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,993,808Phenylcyclopropylamine derivatives and their medical use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,722,743Lysine specific demethylase-1 inhibitors and their use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,149,447Lysine specific demethylase-1 inhibitors and their use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,202,330Lysine Specific DEMETHYLASE-1 Inhibitors and Their Use
In force
 · Low confidence
In forceLow confidence
US 9,708,309Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,233,178Arylcyclopropylamine Based Demethylase Inhibitors of LSD1 and Their Medical Use
In force
 · Medium confidence
In forceMedium confidence
US 9,908,859Lysine demethylase inhibitors for myeloproliferative disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,181,198Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,487,512(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 10 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 6 abandoned · 20 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited